Mesenchymal stem cells in Parkinson’s disease: Motor and nonmotor symptoms in the early posttransplant period

Aliaksandr Boika1, Natallia Aleinikava1, Veranika Chyzhyk1, Marina Zafranskaya2, Darya Nizheharodava2, Vladimir Ponomarev1

Departments of 1Neurology and Neurosurgery, 2Immunology and Biomedical Technology, Belarusian Medical Academy of Postgraduate Education, Minsk, Belarus.

E-mail: Aliaksandr Boika - aboika@tut.by; Natallia Aleinikava - aleina1974@mail.ru; *Veranika Chyzhyk - chyzhykva@gmail.com; Marina Zafranskaya - zafranskaya@gmail.com; Darya Nizheharodava - nzh@tut.by; Vladimir Ponomarev - professor.ponomarev@gmail.com

INTRODUCTION

Parkinson disease (PD) is a chronic, steadily progressive neurodegenerative disease. It leads to severe motor impairment, social disadaptation, and a decrease in the quality of patient's life.

One of the most promising ways of treatment PD is based on the cellular technologies.12,38 Cell therapy for PD was performed for the 1st time in 1979.23 Due to the progress in biotechnology, cell therapy is rapidly becoming a potential treatment option, changing the course of PD in patients.
Numerous experimental and clinical studies into PD therapy reference the application of cells of various origins: dopamine-secreting cells, fetal mesencephalon cells, embryonic stem cells, induced pluripotent stem cells, bone marrow stem cells (hematopoietic and mesenchymal cells), stem cells from other sources, and genetically modified cells. Among them, the use of mesenchymal stem cells (MSCs) is one of the perspective directions of cellular therapy for many neurological disorders for the following reasons:

- MSCs are easily obtained from various tissues.
- MSCs are able to independently migrate to the damaged area when introduced into the human body by different routes of administration.
- MSCs secrete various biological factors necessary for neuroprotection.
- MSCs can differentiate into neuronal phenotypes under appropriate conditions.
- Use of MSCs is not accompanied by ethical problems.

Recently, interest in cell therapy using MSCs in scientific and clinical research has increased exponentially. Clinical trials have demonstrated the possibility of safe transplantation of autologous MSCs in patients with cerebral stroke, multiple sclerosis, cerebral palsy, and amyotrophic lateral sclerosis. In PD, the possibility of introducing MSCs by intracerebral, intra-arterial, intrathecal, and intravenous route has been described. The efficacy of cell therapy using MSCs transplantation was evaluated on animal models with parkinsonism. These studies demonstrated a positive therapeutic effect of both intact and differentiated MSCs on the symptoms of laboratory animal models with parkinsonism, such as the reduction of the motor symptoms, normalization of the level of dopamine and other neurotransmitters, an increase in the number of neurons in the damaged area, and a delay in the disease progression. These encouraging results present a convincing argument to perform similar studies in PD patients.

Two methods of cell implantations that improve the neuroregenerative potential of MSCs with a minimal risk of surgical complications were considered for this study. Local or intranasal transplantation is affordable and minimally invasive. Systemic or intravenous method is advantageous, as it allows to easily perform repeated administrations and stimulate systemic immunomodulatory effects, relevant in conditions of neuroinflammation in PD.

**MATERIALS AND METHODS**

**The timeline of the study**

By the end of 2018, we have successfully completed the preclinical stage of our research. In November 2018, the clinical phase of our study was initiated. On January 17, 2019, the first autologous MSCs transplantation to a patient with PD was performed in the neurosurgical department of our clinical hospital. At present, the number of patients in the posttransplant period has increased to 12. Our objective was to make an assessment of the immediate results of the MSCs introduction effectiveness on motor and nonmotor symptoms in patients with PD.

**The clinical examination of PD patients**

Clinical examination at the selection stage included the clarification of complaints, the history of the disease, neurological examination, and neuroimaging (CT and MRI 1.5 T). In addition, the age of onset of PD, its duration and type of flow, family history of PD, the presence of nonmotor manifestations, chronic inflammatory diseases, significant stressful situations, and work with herbicides in history were specified. Furthermore, the duration of antiparkinsonian drugs usage, the regimen of their administration, the side effects, and another therapy were clarified. The diagnosis of PD was established in all participants of the current study in accordance with the United Kingdom Parkinson's Disease Society Brain Bank clinical diagnostic criteria. The clinical stage of the disease was indicated in the diagnosis in accordance with Hoehn and Yahr scale in the modification of Lindvall et al. (1998). The selection criteria and contraindications listed below are based on the opinions of foreign experts and our own experience.

**The selection criteria:**

1. A reliable diagnosis of Parkinson’s disease, according to, in accordance with, the United Kingdom Parkinson’s Disease Society Brain Bank clinical diagnostic criteria (UK Brain Bank Criteria, 1992)
2. Stage of the disease according to Hoehn and Yahr scale: 1.5–3.0 scores
3. Rapidly progressive type of the flow with changing the stages in no more than 4 years
4. A good response to levodopa treatment: positive dopamine test (difference between motor functions in the on- and off-period not less than 30% by a total score of three parts of the UPDRS scale)
5. The duration of the disease is not more than 8 years with the absence of motor fluctuations and dyskinesia
6. The age of patients is up to 65 years.

**The contraindications:**

1. Parkinsonism and Parkinsonism-plus syndromes
2. Severe concomitant diseases (congestive heart failure, myocardial infarction; pneumonia, decompensated diabetes mellitus, cachexia, etc.)
3. Autoimmune diseases, bleeding, a history of sepsis
4. Oncological diseases
5. An acute stage or exacerbation of the chronic inflammatory process of the sinuses and oral cavity
6. A positive result for HIV, hepatitis B (HBV), hepatitis C (HCV), syphilis (RW)
7. Cognitive deficit (Montreal Cognitive Assessment (MOCA) <26)
8. Mental disorders – hallucinations, behavior disorders
9. Depression of a pronounced degree (not more than 19 points on the Hamilton scale)
10. Alcoholism, drug addiction, criminal liability in the patient's history
11. Pregnancy, lactation.

Collection of the cellular material from patients with PD, who were subject to MSCs transplantation, was performed from the posterior upper crest of an iliac bone according to the standard method.

Preclinical work

Mononuclear cells from bone marrow punctate were isolated by the standard method of separation on the ficoll-verographin gradient ($P = 1.077$). The suspension was centrifuged for 10 min at 1500 rpm/min at room temperature. The pellet was resuspended in 10–15 ml of medium for culturing MSCs. The cell suspension was adjusted to the inoculum concentration with culture medium for MSCs and plated in culture vials. They were placed in a CO$_2$ incubator (37°C, 5% CO$_2$, 90% humidity). After 24–48 h of incubation, cells that had not been adhered to the surface of the vial were washed 3 times with a stream of sterile PBS, after which the vials were filled with specialized medium for culturing MSCs. Every 3–4 days, ½ of the volume of the cultivation medium was changed. At 70–80% confluency stage, the cells were removed from the surface of the culture vial using a trypsin/EDTA solution. Then, they were seeded into plastic sterile vials for adhesive cultures with gas permeable caps to obtain the first passage.

Clinical study

The transplantation of autologous MSCs in patients with PD was performed using two methods, based on the literature data and our own experience with experimental animals in preparation for this study.$^{[23,31,39]}$

a. Systemic (intravenous) administration method: the total dose of cells (0.5–2.0 million/kg of patient's weight) is administered slowly intravenously in three stages with an interval of 7 days
b. Method of tandem (intranasal + intravenous) administration: a suspension of autologous MSCs is administered at a dose of 5.0–12.6 million cells in a volume of 2–5 ml of the prepared solution into the submucous layer of the olfactory epithelium zone from both sides. Seven days after intranasal administration, 10–50 million cells are injected slowly intravenously in two stages with an interval of a week.

The choice between systemic or tandem cell administrations was determined on the individual basis, considering the expected benefits and potential risks.

Effectiveness of the therapy was evaluated before the transplantation (day 0) and after the introduction of MSCs (month 1 and month 3) according to the effect on the motor and nonmotor symptoms. Nonmotor symptoms were assessed with help of the following scales: Hamilton Depression Rating Scale (HDRS), Pittsburgh Sleep Quality Index (PSQI), Epworth Sleepiness Scale (ESS), Nonmotor Symptoms Scale (NMS), and the 39-item Parkinson's Disease Questionnaire (PDQ-39).

The severity of motor symptoms of PD was evaluated on the basis of Section III of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) of the International Society for Movement Disorders (2008). The assessment of motor functions was performed in the morning after a 12–24 h break in taking antiparkinsonian drugs (off-period), then 1 h after they were taken (on-period).

Statistical data processing was performed using the Statistica 8.0 package. The data obtained are presented as the median with an interquartile interval (25–75th percentile). Comparison of the results of the two groups and determination of the statistical significance of the differences were carried out using nonparametric Wilcoxon criteria and the Mann–Whitney U-test. Differences were recognized as statistically significant at $P < 0.05$.

RESULTS

The study group consisted of 12 patients (m:f – 7:5) with a diagnosis of PD, randomized by sex and age, who underwent cell therapy of MSCs in various combinations: systemic or tandem administration. The average age of the patients was 52.0 (39.5; 59.0) years, the duration of the disease was 7.0 (5.0; 8.0) years, the severity of the disease according to the Hoehn and Yahr scale was 2.0 (2.0; 3.0) points. The details of these patients are mentioned in Table 1.

The comparison group included 11 patients (m:f – 6:5) with a diagnosis of PD, randomized by sex and age, received drug treatment with levodopa drugs, dopamine receptor agonists, and amantadine. The control subjects did not receive any injection, including placebo. The average age of the patients was 52.0 (47.5; 62.5) years, the duration of the disease was 6.0 (4.0; 7.0) years, and the severity of the disease on the Hoehn and Yahr scale was 2.0 (2.0; 2.0) points.

There were no statistically significant differences in gender, age, and stage of the disease distribution between the two groups ($P > 0.05$ according to Mann–Whitney U-test).
Table 1: The details of the patients from the study group.

| Sr. no. | Age (years)/sex | Duration of the disease (years) | Stage according to Hoehn and Yahr scale (points) | Type of stem cells | Autologous/allogenic | Dose administered (million cells) | Method | UPDRS score day 0 off/on | Month1 off/on | Month3 off/on | Remarks |
|---------|----------------|-----------------|----------------------------------|-----------------|-----------------|---------------------|--------|----------------|---------------|---------------|---------|
| 1       | 35/M           | 5               | 2                               | MSCs            | Autologous      | 6 intranasally + 21.58 intravenously | Tandem | 34/31          | 30/27         | 32/31         |         |
| 2       | 29/M           | 6               | 2                               | MSCs            | Autologous      | 5.5 intranasally + 38 intravenously  | Tandem | 35/35          | 31/31         | 30/30         |         |
| 3       | 65/M           | 6               | 3                               | MSCs            | Autologous      | 1.6 million/kg intravenously          | Systemic | 80/79        | 74/72         | 71/60         |         |
| 4       | 40/M           | 7               | 2                               | MSCs            | Autologous      | 0.7 million/kg intravenously          | Systemic | 40/34        | 38/34         | 40/32         |         |
| 5       | 57/F           | 7               | 3                               | MSCs            | Autologous      | 8.97 intranasally + 50 intravenously  | Tandem | 57/16        | 52/15         | 49/15         | Catch a cold between day 0 and month 1 |
| 6       | 65/F           | 6               | 2                               | MSCs            | Autologous      | 12.6 intranasally + 22 intravenously  | Tandem | 27/10        | 9/8           | 12/8          |         |
| 7       | 62/F           | 2               | 3                               | MSCs            | Autologous      | 1.0 million/kg intravenously          | Systemic | 34/24       | 25/15         | 25/16         |         |
| 8       | 58/F           | 8               | 2                               | MSCs            | Autologous      | 0.5 million/kg intravenously          | Systemic | 36/31       | 27/23         | 27/21         |         |
| 9       | 38/M           | 5               | 2                               | MSCs            | Autologous      | 10 intranasally + 33.75 intravenously | Tandem | 26/15        | 23/18         | 23/18         |         |
| 10      | 48/M           | 5               | 2                               | MSCs            | Autologous      | 10 intranasally + 45 intravenously    | Tandem | 30/15        | 16/14         | 16/12         |         |
| 11      | 45/M           | 8               | 2                               | MSCs            | Autologous      | 0.5 million/kg intravenously          | Systemic | 57/13       | 57/13         | 32/12         | Catch a cold between day 0 and month 1 |
| 12      | 56/F           | 4               | 2                               | MSCs            | Autologous      | 0.8 million/kg intravenously          | Systemic | 38/24       | 36/26         | 38/19         |         |

The day before the transplantation – day 0, 1 month after the introduction of MSCs – month 1, 3 months after the introduction of MSCs – month 3, Section III of the Unified Parkinson’s Disease Rating Scale of the International Society for Movement Disorders (2008) – UPDRS, mesenchymal stem cells – MSCs
We revealed statistically significant differences ($P = 0.02$) between the MDSUPDRS score (Section III) before treatment ($Me = 36.5 \ [30.0; 57.5]$) and the score in month 1 ($Me = 33.5 \ [26.0; 52.5]$) in the off-period in the study group. The difference amounted to 9%. The achieved result was maintained for 3 months after transplantation ($Me = 32.0 \ [23.0; 40.0]$). In the on-period, statistically significant differences between the score before therapy ($Me = 20.0 \ [15.5; 34.0]$) and month 1 ($Me = 22.0 \ [14.5; 31.0]$), ($P = 0.18$), and in month 1 and month 3 ($Me = 19.0 \ [15.0; 31.0]$), ($P = 0.2$) were not detected.

In the comparison group, statistically significant differences between the score in day 0 ($Me = 20.0 \ [15.5; 34.0]$) and in month 1 ($Me = 22.0 \ [14.5; 31.0]$), ($P = 0.18$), and in month 1 and month 3 ($Me = 19.0 \ [15.0; 31.0]$), ($P = 0.2$) were not detected both in the off- and on-periods.

An improvement of mood, significant decrease in daytime sleepiness, and the patients’ sleep quality were identified in the study group. By month 1, 36% decrease in score according to the Hamilton depression scale was observed compared to day 0 ($P = 0.02$). The improvement of mood and a decreased depressive mood were also detected after 3 months ($P = 0.01$) and amounted to 44%. By the month 3, sleep quality assessed by the PSQI scale, improved by 46% compared to the initial data, and daytime sleepiness, assessed by the Epworth scale, decreased by 42% [Table 2].

There was also a statistically significant increase ($P = 0.003$) in the overall quality of life by the PDQ-39 scale. The achieved result was maintained for 3 months after transplantation ($P = 0.01$).

There was no statistically significant difference when assessing the same symptoms in the dynamics in the comparison group ($P \geq 0.05$) [Table 3].

Effectiveness of the therapy was also assessed by the NMS scale. A tendency toward a decreased total number of nonmotor manifestations of PD between day 0 ($Me = 8.0 \ [6.0; 13.5]$) and month 3 ($Me = 7.0 \ [6.0; 10.5]$) [Table 1] has also been revealed. In contrast, the patients from the comparison group during the same observation period showed a tendency to the symptoms' increase [Table 3].

**DISCUSSION**

At present, it is established that MSCs, similar to leukocytes, express a variety of receptors and cell adhesion molecules involved in homing and migration to the lesion sites both with local and systemic routes of administration.\[6,13,22,29\]

Experimental models of rodents have shown that if introduced through the intranatal route, MSCs are able to migrate to the brain as early as the 1st day after the administration and are present at the lesion site for 3 weeks or more.\[26,31,39\] In these studies, the implanted stem cells have shown a pronounced neurotrophic effect by producing growth factors, such as GDNF, BDNF, NGF, IGF-1, and VEGF. In addition, there is ample evidence that MSCs support the structural organization of both individual brain cells and the neuronal network as a whole, and contribute to the survival of neurons and oligodendrocytes in neurodestructive conditions.\[10\] Moreover, by exerting an immunoregulatory effect on both local and systemic levels,\[5\] MSCs decrease the inflammatory response from microglial cells, and, thus, restore the functional activity of neurons.\[17,20\]

At present, only preliminary data are available on the use of MSCs in human PD.\[30\] In an open-label study in 2010, Indian researchers administered 106 autologous bone marrow-derived MSCs per kilogram body weight unilaterally into the sublateral ventricular zone through stereotactic surgery in seven patients with PD.\[44\] The procedure was well tolerated. Three out of seven patients were reported to have lasting improvement in the unified Parkinson's disease rating scale and other rating scales compared to baseline. In agreement with our findings, this study also demonstrates that intranasal and tandem (intranasal + intravenous) methods of

---

**Table 2: The intensity of nonmotor symptoms in the study group before the transplantation, 1 month, and 3 months after the introduction of MSCs (Me, Q25-Q75).**

| Study group, n=12 | Observation period | P-value |
|-------------------|--------------------|---------|
|                   | Day 0              | Month 1 | Month 3 |
|                   | 1                  | 2       | 3       |
| HDRS              | 12.5 [9.0;19.5]    | 8.0 [4.0;10.0] | 7.0 [5.0;8.0] | $P_{1,2}=0.02; P_{1,3}=0.01; P_{2,3}=0.52$ |
| PSQI              | 5.5 [2.5;14.0]     | 4.5 [1.5;11.0] | 3.0 [3.0;11.0] | $P_{1,2}=0.24; P_{1,3}=0.17; P_{2,3}=0.79$ |
| ESS               | 12.0 [6.0;13.5]    | 7.5 [5.0;10.0] | 7.0 [6.0;10.5] | $P_{1,2}=0.01; P_{1,3}=0.02; P_{2,3}=0.07$ |
| NMS               | 8.0 [6.0;13.5]     | 7.5 [5.0;10.0] | 7.0 [6.5;10.0] | $P_{1,2}=0.06; P_{1,3}=0.41; P_{2,3}=0.86$ |
| PDQ-39SI          | 45.5[33.9;50.3]    | 31.7[22.8;41.3] | 32.1[28.4;36.5] | $P_{1,2}=0.003; P_{1,3}=0.01; P_{2,3}=0.79$ |

The Wilcoxon signed-rank test used to compare two related samples: 1 and 2, 2 and 3, 1 and 3. The day before the transplantation – day 0, 1 month after the introduction of MSCs – month 1, 3 months after the introduction of MSCs – month 3, HDRS: Hamilton Depression Rating Scale, PSQI: Pittsburgh Sleep Quality Index, ESS: Epworth Sleepiness Scale, NMS: Nonmotor Symptoms Scale, PDQ-39SI: 39-item Parkinson’s Disease Questionnaire Summary Index

---

**Surgical Neurology International • 2020 • 11(380) • 5**
autologous MSCs administration are safe and have beneficial neuroprotective and neurorestorative effects.

At this stage of the study, given a short period of the postoperative follow-up, we cannot fully exclude the influence of the possible placebo effect, which most often occurs in the early stages of open research. Patient evaluation using standardized scales and a long period of posttransplant observation will help to answer this question definitively.

Undoubtedly, the data obtained are only preliminary, and there is a need for more detailed and lengthy study. In future, an additional set of evaluation studies is planned, along with an increased number of the transplanted MSCs.

Due to the fact that the lifetime of MSCs in the body is limited to several weeks, it is important to study the long-term effects of their transplantation in PD, the effectiveness of repeated MSCs reintroduction, and the time intervals over which they must be carried out.

**CONCLUSION**

The treatment of patients with PD with the use of MSCs has produced encouraging results that suggest influence on many symptoms of the PD pathogenesis, as well as their capability to modify the course of the disease and provide control over the manifestations of the motor symptoms of the disease. Our data demonstrate a decrease in the severity of motor and nonmotor symptoms of the disease in the posttransplant period. These encouraging results allow us to consider the application of MSCs in PD as a therapy modifying the course of the disease. However, this method of PD treatment is not a fully understood process, which requires additional studies and a longer follow-up period in the posttransplant period.

**Declaration of patient consent**

Patient’s consent not required as patients identity is not disclosed or compromised.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**REFERENCES**

1. Aleinikava NE, Boika AV, Nizheharodava DB, Ponomarev VV, Vanslau MI, Ustiamchuk AM, et al. The obtaining of toxic chronic model of Parkinsonism syndrome in rats. Vestnik VSMU 2018;17:92-9.
2. Barzilay R, Kan I, Ben-Zur T, Bulvik S, Melamed E, Offen D. Induction of human mesenchymal stem cells into dopamine-producing cells with different differentiation protocols. Stem Cells Dev 2008;17:547-54.
3. Blandini F, Cova L, Armentero MT, Zennaro E, Levandis G, Bossolasco P, et al. Transplantation of undifferentiated human mesenchymal stem cells protects against 6-hydroxydopamine neurotoxicity in the rat. Cell Transplant 2010;19:203-17.
4. Brazzini A, Cantella R, De la Cruz A, Yupanqui J, León C, Jorquiera T, et al. Intracellular autologous implantation of adult stem cells for patients with Parkinson disease. J Vasc Interv Radiol 2010;21:443-51.
5. Castro-Manreza ME, Montesinos JJ. Immunoregulation by mesenchymal stem cells: Biological aspects and clinical applications. J Immuno Res 2015;2015:394917.
6. Chen D, Fu W, Zhuang W, Lv C, Li F, Wang XJ. Therapeutic effects of intranigral transplantation of mesenchymal stem cells in rat models of Parkinson's disease. J Neurosci Res 2017;95:907-17.
7. Connick P, Kolappan M, Crawley C, Webber DJ, Patani R, Michell AW, et al. Autologous mesenchymal stem cells for patients with Parkinson disease. J Vasc Interv Radiol 2010;21:443-51.
8. De Becker A, Riet IV. Homing and migration of mesenchymal stromal cells: How to improve the efficacy of cell therapy? World J Stem Cells 2016;8:73-87.
9. Gao R, Zhang G, Chen X, Yang A, Smith G, Wong DF, et al.
CSF biomarkers and its associations with 18F-AV133 cerebral VMAT2 binding in Parkinson's disease—a preliminary report. PLoS One 2016;11:e0164762.

10. Goetz CG, Wuu J, McDermott MP, Adler CH, Fahn S, Freed CR, et al. Placebo response in Parkinson's disease: Comparisons among 11 trials covering medical and surgical interventions. Mov Disord 2008;23:690-9.

11. Hayashi T, Wakao S, Kitada M, Ose T, Watabe H, Kuroda Y, et al. Autologous mesenchymal stem cell-derived dopaminergic neurons function in Parkinsonian macaques. J Clin Invest 2013;123:272-84.

12. Hellmann MA, Panet H, Barhum Y, Malmback E, Offen D. Increased survival and migration of engrafted mesenchymal bone marrow stem cells in 6-hydroxydopamine-lesioned rodents. Neurosci Lett 2006;395:124-8.

13. Honczarenko M, Le Y, Swierkowski M, Ghiran I, Gloor DE, Silberstein LE. Human bone marrow stromal cells express a distinct set of biologically functional chemokine receptors. Stem Cells 2006;24:1030-41.

14. Huang L, Zhang C, Gu J, Wu W, Shen Z, Zhou X, et al. A randomized, placebo-controlled trial of human umbilical cord blood mesenchymal stem cell infusion for children with cerebral palsy. Cell Transplant 2018;27:325-34.

15. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: A clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-4.

16. Jones EA, Kinsey SE, English A, Jones RA, Straszynski L, Meredith DM, et al. Isolation and characterization of bone marrow multipotent mesenchymal progenitor cells. Arthritis Rheum 2002;46:3349-60.

17. Jose S, Tan SW, Ooi YY, Ramasamy R, Vidyadaran S. Mesenchymal stem cells exert anti-proliferative effect on lipopolysaccharide-stimulated BV2 microglia by reducing tumour necrosis factor-α levels. J Neuroinflammation 2014;11:149.

18. Koniusz S, Andrzejeewska A, Muraca M, Srivastava AK, Janowski M, Lukomska B, et al. Extracellular vesicles in physiology, pathology, and therapy of the immune and central nervous system, with focus on extracellular vesicles derived from mesenchymal stem cells as therapeutic tools. Front Cell Neurosci 2016;10:109.

19. Lee JS, Hong JM, Moon GJ, Lee P, Ahn YH, Bang OY, et al. A long-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke. Stem Cells 2010;28:1099-106.

20. Liu Y, Zhang R, Yan K, Chen F, Huang W, Lv B, et al. Mesenchymal stem cells inhibit lipopolysaccharide-induced inflammatory responses of BV2 microglial cells through TSG-6. J Neuroinflammation 2014;11:135.

21. Mazzini L, Mareschi K, Ferrero I, Miglioretti M, Stecco A, Servo S, et al. Mesenchymal stem cell transplantation in amyotrophic lateral sclerosis: A long-term safety study. Cytotherapy 2012;14:56-60.

22. Nitzsche F, Müller C, Lukomska B. Concise review: MSC adhesion cascade-insights into homing and transendothelial migration. Stem Cells 2017;35:1446-60.

23. Perlow MJ, Freed WJ, Hoffer BJ, Seiger A, Seiger A, Olson L, et al. Brain grafts reduce motor abnormalities produced by destruction of nigrostriatal dopamine system. Science 1979;204:643-7.

24. Ponomarev VV, Boyko AV, Zafranskaya MM, D, Aleynikova NE, Chyzhyk VA, et al. Assessment of Cell Therapy Effectiveness in Patients with Parkinson's Disease using Different Cell Transplantation Routs. Minsk: Belarusian State Medical University; 2019. p. 132-6.

25. Salama M, Sobh M, Emam M, Abdalla A, Sabry D, El-Gamal M, et al. Effect of intranasal stem cell administration on the nigrostriatal system in a mouse model of Parkinson’s disease. Exp Ther Med 2017;13:976-82.

26. Shanko Y, Navitskaya V, Zamaro A, Zafranskaya M, Krivenko S, Koulchitsky S, et al. Somatotopic principle of perineural implantation of stem cells in patients with brain injuries. J Neurol Stroke 2018;8:259-61.

27. Shanko YG, Kulchitsky VA, Novitskaya VV, Tokalchik YP, Zafranskaya MM, Krivenko SI, et al. Stem cells in the treatment of cerebral infarction: An analytical review of the literature. Med Novosti 2019;1:9-11.

28. Shen Y, Huang J, Liu L, Xu X, Han C, Zhang G, et al. A compendium of preparation and application of stem cells in Parkinson's disease: Current status and future prospects. Front Aging Neurosci 2016;8:117.

29. Sohni A, Verfaillie CM. Mesenchymal stem cells migration homing and tracking. Stem Cells Int 2013;2013:130763.

30. Staff NP, Jones DT, Singer W. Mesenchymal stromal cell therapies for neurodegenerative diseases. Mayo Clin Proc 2019;94:892-905.

31. Stukach YP, Shanko, YG, Parkhach, LP, Pashekhivg SV, Kulchitckiy VA. The technology of delivery mesenchymal stem cells to different parts of the brain in the anterior or posterior cranial fossa. In: Medical Electronics and New Medical Technologies: A Collection of Scientific Articles 9th International Scientific and Technical Conference. Minsk: Beloruskii Gosudarstvennyii Universitet Informatiki I Radioelektroniki; 2016. p. 121-4.

32. Tozzi A, De Iure A, Bagetta V, Tantucci M, Durante V, Quiroga-Varela A, et al. Alpha-synuclein produces early behavioral alterations via striatal cholinergic synaptic dysfunction by interacting with GluN2D N-Methyl-D-aspartate receptor subunit. Biol Psychiatry 2016;79:402-14.

33. Ullah I, Subbarao RB, Rho GJ. Human mesenchymal stem cells-current trends and future prospective. Biosci Rep 2015;35:e00191.

34. Venkataramana NK, Kumar SK, Balaraju S, Radhakrishnan RC, Bansal A, Dixit A, et al. Open-labeled study of unilateral autologous bone-marrow-derived mesenchymal stem cell transplantation in Parkinson's disease. Transl Res 2010;155:62-70.

35. Venkataramana NK, Pal R, Rao SA, Naik AL, Jan M, Nair R, et al. Bilateral transplantation of allogeneic adult human bone marrow-derived mesenchymal stem cells into the subventricular zone of Parkinson's disease: A pilot clinical study. Stem Cells Int 2012;2012:931902.

36. Wang F, Yasuhara T, Shingo T, Kameda M, Tajiri N, Yuan WJ, et al. Intravenous administration of mesenchymal stem cells exerts therapeutic effects on parkinsonian model of rats: Focusing on neuroprotective effects of stromal cell-derived placental growth factor.
factor-1alpha. BMC Neurosci 2010;11:52.
37. Wang LT, Ting CH, Yen ML, Liu KJ, Sytwu HK, Wu KK, et al. Human mesenchymal stem cells (MSCs) for treatment towards immune- and inflammation-mediated diseases: Review of current clinical trials. J Biomed Sci 2016;23:76.
38. Yasuhara T, Kameda M, Sasaki T, Tajiri N, Date I. Cell therapy for Parkinson’s disease. Cell Transplant 2017;26:1551-9.
39. Zafranskaya MM, Nizhegorodova DB, Aleynikova NE, Kuznetsova TE, Vanslav MI, Ignatovich TV, et al. The migration of multipotent mesenchymal stromal cells after systemic and local administration in an experimental model of Parkinson’s disease. Ann Clin Exp Neurol 2019;13:32-40.

How to cite this article: Boika A, Aleinikava N, Chyzhyk V, Zafranskaya M, Nizheharodava D, Ponomarev V. Mesenchymal stem cells in Parkinson’s disease: Motor and nonmotor symptoms in the early posttransplant period. Surg Neurol Int 2020;11:380.